Sovaldi (Sofosbuvir)
Direct-Acting Antiviral for Hepatitis C Treatment
Sovaldi (sofosbuvir) is a prescription direct-acting antiviral medication used in combination with other drugs to treat chronic hepatitis C virus (HCV) infection. Approved for adults and children aged 3 years and older, sofosbuvir works by blocking the NS5B RNA polymerase enzyme that the hepatitis C virus needs to replicate. With cure rates exceeding 90% in many patient populations, Sovaldi-based regimens have transformed hepatitis C from a chronic, progressive liver disease into a curable condition.
Quick Facts: Sovaldi
Key Takeaways
- Sovaldi (sofosbuvir) is a direct-acting antiviral that treats chronic hepatitis C by blocking viral replication, achieving cure rates above 90% in combination therapy.
- It must always be used in combination with other hepatitis C medications such as ribavirin or peginterferon alfa — sofosbuvir alone is not effective.
- Treatment duration is typically 12 to 24 weeks, depending on HCV genotype, liver condition, and prior treatment history.
- Certain drugs including rifampicin, St. John’s wort, and amiodarone must be avoided due to dangerous interactions.
- When used with ribavirin, pregnancy must be strictly avoided due to the risk of serious birth defects from ribavirin.
What Is Sovaldi and What Is It Used For?
Hepatitis C is a viral infection that primarily affects the liver, caused by the hepatitis C virus (HCV). If left untreated, chronic hepatitis C can lead to serious liver damage including cirrhosis, liver failure, and hepatocellular carcinoma (liver cancer). The World Health Organization estimates that approximately 58 million people worldwide have chronic hepatitis C infection, with about 1.5 million new infections occurring each year.
Sovaldi contains the active substance sofosbuvir, which belongs to a class of medications known as direct-acting antivirals (DAAs). Specifically, sofosbuvir is a nucleotide analogue inhibitor of the HCV NS5B RNA-dependent RNA polymerase. This enzyme is essential for the hepatitis C virus to copy its genetic material and produce new virus particles. By blocking this enzyme, sofosbuvir effectively halts viral replication, allowing the body’s immune system to clear the remaining virus from the bloodstream.
Sofosbuvir is considered a pan-genotypic antiviral, meaning it is effective against all six major genotypes of hepatitis C (genotypes 1 through 6). This broad-spectrum activity makes it a versatile component of hepatitis C treatment regimens worldwide. Clinical trials have demonstrated sustained virologic response (SVR) rates — the medical term for a functional cure — exceeding 90% in many patient populations when sofosbuvir is used as part of combination therapy.
Sovaldi is always used in combination with other medications for the treatment of hepatitis C. It does not work effectively when used alone. The most common combination regimens include:
- Sofosbuvir + ribavirin — used in both adults and children, typically for 12 to 24 weeks depending on the genotype and patient factors.
- Sofosbuvir + peginterferon alfa + ribavirin — used in adult patients, particularly for certain genotypes where this triple combination achieves optimal cure rates.
The introduction of sofosbuvir in 2013 marked a paradigm shift in hepatitis C treatment. Prior to DAAs, treatment relied heavily on interferon-based regimens that were associated with significant side effects, lengthy treatment durations, and cure rates of only 40–50%. Sofosbuvir-based regimens dramatically improved both the efficacy and tolerability of hepatitis C treatment, contributing to the WHO’s goal of eliminating hepatitis C as a public health threat by 2030.
Sovaldi is approved for use in adults and children aged 3 years and older. The tablet formulation (400 mg) is typically used for adults and older children who can swallow tablets, while the oral granule formulations (150 mg and 200 mg sachets) are available for younger children who may have difficulty swallowing tablets.
What Should You Know Before Taking Sovaldi?
Contraindications
You should not take Sovaldi if you are allergic to sofosbuvir or any of the other ingredients in the medication. Allergic reactions can range from mild skin rashes to severe hypersensitivity reactions. If you have previously experienced an allergic reaction to sofosbuvir, you must inform your doctor immediately.
Sovaldi must not be taken concurrently with any of the following medications, as they significantly reduce sofosbuvir blood levels and can render the treatment ineffective:
- Rifampicin — an antibiotic used for tuberculosis and other infections. Rifampicin is a potent inducer of P-glycoprotein and CYP enzymes that dramatically reduce sofosbuvir levels.
- St. John’s wort (Hypericum perforatum) — a herbal remedy commonly used for mild depression. It induces drug-metabolizing enzymes and transporters, reducing sofosbuvir efficacy.
- Carbamazepine — an anticonvulsant used for epilepsy and neuropathic pain.
- Phenobarbital — a barbiturate anticonvulsant used for seizure prevention.
- Phenytoin — an anticonvulsant used for epilepsy and seizure disorders.
If you are currently taking any of these medications, you must inform your doctor immediately before starting Sovaldi treatment. Your doctor will need to consider alternative medications or treatment strategies.
Warnings and Precautions
Because Sovaldi must always be used in combination with other hepatitis C medications, you should also carefully read the prescribing information for those companion drugs. The following warnings and precautions are particularly important:
Amiodarone and Cardiac Risk
If you are currently taking, or have recently taken, the heart medication amiodarone (used for irregular heartbeat), you are at risk of developing life-threatening bradycardia (dangerously slow heart rate) when starting sofosbuvir-containing regimens. Your doctor may consider alternative heart medications, or if Sovaldi treatment is essential, extended cardiac monitoring may be required. Seek immediate medical attention if you experience any of the following symptoms during treatment:
- Slow or irregular heartbeat, or heart rhythm problems
- Shortness of breath or worsening of existing breathlessness
- Chest pain
- Dizziness or lightheadedness
- Heart palpitations (feeling your heart beating rapidly or irregularly)
- Near-fainting episodes or actual loss of consciousness
Other Liver Conditions
If you have liver problems beyond hepatitis C, such as co-infection with hepatitis B virus, other forms of liver disease, or if you are awaiting a liver transplant, your doctor needs to know. In patients with hepatitis B co-infection, there have been reports of hepatitis B reactivation during or after hepatitis C treatment with DAAs, which can be serious and potentially life-threatening. Your doctor may need to monitor you more closely or prescribe hepatitis B antiviral therapy.
Diabetes
If you have diabetes, your blood glucose levels should be monitored carefully during and after starting Sovaldi treatment. Some patients with diabetes have experienced hypoglycemia (low blood sugar) after starting direct-acting antiviral therapy for hepatitis C. This may be related to improvements in liver function as the hepatitis C infection is treated. Your diabetes medications may need to be adjusted.
Blood Tests and Monitoring
Your doctor will perform blood tests before, during, and after your treatment with Sovaldi. These tests serve several purposes: determining which companion medications and treatment duration are most appropriate for you, monitoring for side effects, and confirming that the treatment has been successful by checking that the hepatitis C virus is no longer detectable in your blood.
Pregnancy and Breastfeeding
Sovaldi is almost always used together with ribavirin, which is known to cause serious birth defects and fetal death. Pregnancy must be avoided during ribavirin-containing treatment and for at least 6 months after treatment ends. Both female patients and female partners of male patients taking ribavirin must use effective contraception.
If you or your partner becomes pregnant during treatment with Sovaldi and ribavirin, or within the months following treatment completion, contact your doctor immediately. It is essential to read the pregnancy section of the ribavirin prescribing information thoroughly and discuss appropriate contraceptive methods with your healthcare provider before starting treatment.
It is not known whether sofosbuvir passes into breast milk. Therefore, breastfeeding is not recommended during treatment with Sovaldi. Discuss the risks and benefits with your doctor if you are breastfeeding or planning to breastfeed.
Use in Children
Sovaldi is approved for children aged 3 years and older. The oral granule formulation was specifically developed for younger children who cannot swallow tablets. The use of sofosbuvir in children under 3 years of age has not been studied, and the medication should not be given to children in this age group.
Driving and Operating Machinery
When Sovaldi is taken with other hepatitis C medications, patients have reported fatigue, dizziness, blurred vision, and impaired concentration. If you experience any of these effects, you should avoid driving, cycling, or operating machinery until you know how the treatment affects you.
How Does Sovaldi Interact with Other Drugs?
Drug interactions are a critical consideration when prescribing Sovaldi. Sofosbuvir is a substrate of the drug transporter P-glycoprotein (P-gp). Drugs that are potent P-gp inducers can significantly reduce sofosbuvir plasma concentrations and diminish its therapeutic effect. Additionally, because successful treatment of hepatitis C can improve liver function, this may affect the metabolism of other medications you take.
Major Interactions — Contraindicated
The following drugs must not be used with Sovaldi because they drastically reduce sofosbuvir levels, potentially leading to treatment failure and the development of drug-resistant hepatitis C virus:
| Drug | Drug Class | Reason | Severity |
|---|---|---|---|
| Rifampicin | Antibiotic (anti-TB) | Potent P-gp inducer; dramatically reduces sofosbuvir levels | Contraindicated |
| St. John’s wort | Herbal supplement | Induces P-gp and CYP enzymes; reduces sofosbuvir efficacy | Contraindicated |
| Carbamazepine | Anticonvulsant | Strong P-gp inducer; may cause treatment failure | Contraindicated |
| Phenobarbital | Anticonvulsant | Potent enzyme inducer; significantly lowers sofosbuvir levels | Contraindicated |
| Phenytoin | Anticonvulsant | Strong P-gp inducer; reduces antiviral efficacy | Contraindicated |
Serious Interactions — Use with Extreme Caution
| Drug | Drug Class | Reason | Action Required |
|---|---|---|---|
| Amiodarone | Antiarrhythmic | Risk of life-threatening symptomatic bradycardia | Avoid if possible; cardiac monitoring required |
| Oxcarbazepine | Anticonvulsant | May reduce sofosbuvir plasma concentrations | Discuss alternatives with prescriber |
| Modafinil | Wakefulness agent | May reduce sofosbuvir plasma concentrations | Discuss alternatives with prescriber |
| Rifapentine | Antibiotic (anti-TB) | May reduce sofosbuvir plasma concentrations | Discuss alternatives with prescriber |
Other Notable Interactions
Warfarin and vitamin K antagonists: The anticoagulant effect of warfarin may change during hepatitis C treatment because improving liver function affects the production of clotting factors. Your doctor may need to monitor your INR (International Normalized Ratio) more frequently and adjust your warfarin dose accordingly.
Immunosuppressants: Patients who have received a liver transplant and are taking immunosuppressive medications (such as ciclosporin or tacrolimus) may require dose adjustments as liver function improves during hepatitis C treatment. Your transplant team should closely monitor drug levels throughout therapy.
Always inform your doctor or pharmacist about all medications you are taking, including prescription drugs, over-the-counter medications, vitamins, and herbal supplements, before starting Sovaldi treatment.
What Is the Correct Dosage of Sovaldi?
Always take Sovaldi exactly as your doctor has prescribed. The dosage, combination therapy, and treatment duration depend on several factors including your HCV genotype, whether you have cirrhosis, prior treatment history, and your overall health status. Do not change your dose or stop taking the medication without consulting your doctor.
Adults
Standard Adult Dose
Sovaldi 400 mg tablet: One tablet taken once daily, with food. The tablet should be swallowed whole with water. Treatment is always given in combination with other hepatitis C medications.
| Patient Group | Formulation | Dose | Duration |
|---|---|---|---|
| Adults (all genotypes) | 400 mg tablet | 400 mg once daily | 12–24 weeks |
| Children ≥35 kg | 400 mg tablet | 400 mg once daily | 12–24 weeks |
| Children 17–<35 kg | 200 mg granules | 200 mg once daily | 12–24 weeks |
| Children <17 kg | 150 mg granules | 150 mg once daily | 12–24 weeks |
Children (3 Years and Older)
The dosage for children depends on body weight. Children weighing 35 kg or more can take the adult 400 mg tablet. For younger or lighter children, oral granule sachets are available in 150 mg and 200 mg strengths. Your doctor will determine the appropriate dose based on your child’s weight.
The oral granules can be administered in several ways to help children swallow the medication:
- With non-acidic food: Empty the entire sachet onto one or more spoonfuls of non-acidic soft food such as chocolate syrup, mashed potatoes, or ice cream at or below room temperature. Mix gently and administer within 30 minutes. The granules should be swallowed without chewing to avoid the bitter taste.
- With water: The granules can be placed directly in the mouth and swallowed without chewing, followed by water. Do not use acidic beverages such as fruit juices (apple, cranberry, grapefruit, orange, or pineapple juice).
- Without food or water: The granules can be taken directly into the mouth and swallowed whole without chewing.
Sovaldi should not be used in children under 3 years of age, as the safety and efficacy in this age group have not been established.
Elderly Patients
No dose adjustment is required for elderly patients. Clinical trials included patients over 65 years of age, and no clinically significant differences in safety or efficacy were observed compared to younger adults. However, elderly patients may be more likely to have reduced kidney function, and this should be taken into consideration.
Patients with Kidney Problems
Inform your doctor if you have kidney problems or are on dialysis. No dose adjustment is required for patients with mild to moderate renal impairment. For patients with severe renal impairment (eGFR less than 30 mL/min/1.73m²) or on hemodialysis, the safety and appropriate dosing of sofosbuvir have not been fully established, and your doctor will weigh the benefits and risks carefully.
Missed Dose
- If you notice within 18 hours of your usual dosing time: Take the missed dose as soon as possible, then continue with your regular schedule.
- If more than 18 hours have passed: Skip the missed dose and take the next one at your regular time.
- Never take a double dose to make up for a missed one.
It is important not to miss doses of Sovaldi, as consistent dosing helps ensure the hepatitis C virus is effectively suppressed and reduces the risk of developing drug resistance. Setting a daily alarm or using a pill organizer can help you remember to take your medication at the same time each day.
Overdose
If you accidentally take more than the prescribed dose of Sovaldi, contact your doctor or nearest emergency department immediately for advice. Bring the medication packaging with you so that medical staff can easily identify what you have taken and in what quantity.
Do not stop taking Sovaldi unless your doctor tells you to do so. Completing the full course of treatment is essential to give the medication the best chance of curing your hepatitis C infection. Stopping early may result in the virus not being fully eliminated and could increase the risk of developing resistant virus strains.
What Are the Side Effects of Sovaldi?
Like all medicines, Sovaldi can cause side effects, although not everyone experiences them. It is important to note that most side effects reported during Sovaldi treatment are attributable to the companion medications (ribavirin or peginterferon alfa and ribavirin) rather than sofosbuvir itself. In clinical trials, sofosbuvir alone showed a very favorable safety profile.
Side Effects When Used with Amiodarone
When Sovaldi is taken together with amiodarone (a heart rhythm medication), there is a risk of symptomatic bradycardia (dangerously slow heart rate) that can be life-threatening. Seek immediate medical attention if you experience slow or irregular heartbeat, shortness of breath, chest pain, dizziness, or fainting.
Side Effects When Used with Ribavirin or Peginterferon + Ribavirin
Very Common
May affect more than 1 in 10 people
- Fatigue and irritability
- Headache
- Nausea, vomiting, diarrhea
- Insomnia (difficulty sleeping)
- Decreased appetite
- Skin rash and itching
- Dizziness
- Muscle pain, joint pain
- Shortness of breath, cough
- Fever, chills, flu-like symptoms
- Anemia (low red blood cell count)
- Neutropenia (low white blood cell count)
- Thrombocytopenia (low platelet count)
- Elevated bilirubin levels
Common
May affect up to 1 in 10 people
- Mood changes, depression, anxiety, agitation
- Blurred vision
- Severe headache (migraine), memory loss, difficulty concentrating
- Weight loss
- Shortness of breath during physical activity
- Stomach discomfort, constipation, dry mouth, indigestion, acid reflux
- Hair loss and thinning hair
- Dry skin
- Back pain, muscle spasms
- Chest pain, feeling of weakness
- Common cold (nasopharyngitis)
Frequency Not Known
Cannot be estimated from available data
- Stevens-Johnson syndrome — widespread severe skin rash with peeling skin, potentially accompanied by fever, flu-like symptoms, blisters in the mouth, eyes, and/or genitals. This is a medical emergency requiring immediate treatment.
Blood Test Abnormalities
Blood tests during treatment may show several changes that your doctor will monitor:
- Anemia (low red blood cells): Signs may include tiredness, headache, and shortness of breath during exercise. This is primarily caused by ribavirin.
- Neutropenia (low white blood cells): Signs may include increased susceptibility to infections, including fever, chills, sore throat, or mouth ulcers. This is primarily related to peginterferon alfa.
- Thrombocytopenia (low platelets): May increase the risk of bruising or bleeding.
- Elevated bilirubin: Changes in liver enzyme levels may be detected through blood tests.
If any side effect becomes severe or bothersome, or if you notice any effects not listed here, contact your doctor or pharmacist. Reporting suspected side effects helps authorities continuously monitor the benefit-risk balance of the medication.
How Should You Store Sovaldi?
Proper storage of Sovaldi helps ensure the medication remains effective throughout your treatment course. Follow these guidelines:
- Keep out of sight and reach of children at all times.
- No special storage conditions are required — store at room temperature.
- Do not use this medicine after the expiration date stated on the sachet or carton. The expiration date refers to the last day of that month.
- Do not dispose of medications via wastewater or household waste. Ask your pharmacist about proper disposal of medications you no longer use. These measures help protect the environment.
If you notice any change in the appearance of the tablets or granules (such as discoloration, crumbling, or unusual odor), do not take them. Instead, consult your pharmacist about obtaining a replacement.
What Does Sovaldi Contain?
Sovaldi contains sofosbuvir as its active pharmaceutical ingredient. The formulation also contains several inactive (excipient) ingredients that help with manufacturing, stability, and drug delivery:
Oral Granules (150 mg and 200 mg Sachets)
The coated granules are white to off-white and are supplied in individual sachets. The inactive ingredients include:
- Lactose monohydrate
- Microcrystalline cellulose
- Croscarmellose sodium
- Hydroxypropyl cellulose
- Colloidal anhydrous silica
- Sodium stearyl fumarate
- Hypromellose
- Macrogol 400
- Amino methacrylate copolymer
- Talc
- Stearic acid
- Sodium lauryl sulfate
Sovaldi granules contain lactose. If you have been told by your doctor that you have an intolerance to certain sugars, contact your doctor before taking this medicine. The granules contain less than 1 mmol (23 mg) sodium per sachet, meaning they are essentially sodium-free.
Packaging
Sovaldi oral granules are available in an outer carton containing 28 sachets. The film-coated tablets are available as yellow, capsule-shaped tablets debossed with “GSI” on one side and “7977” on the other side, supplied in bottles of 28 tablets.
Sovaldi is manufactured by Gilead Sciences Ireland UC, Carrigtohill, County Cork, Ireland.
Frequently Asked Questions About Sovaldi
Sovaldi (sofosbuvir) is a direct-acting antiviral medication used to treat chronic hepatitis C virus (HCV) infection. It is effective against all major HCV genotypes (1 through 6) and is used in combination with other antiviral medications such as ribavirin or peginterferon alfa plus ribavirin. It is approved for use in adults and children aged 3 years and older.
When taken with ribavirin or peginterferon alfa, the most common side effects include fatigue, headache, nausea, insomnia, diarrhea, decreased appetite, skin rash, itching, dizziness, and muscle or joint pain. These side effects are mostly related to the companion medications rather than sofosbuvir itself.
Yes. Sovaldi-based treatment regimens achieve sustained virologic response (SVR) rates of 90% or higher in many patient populations, which is considered a functional cure of hepatitis C. SVR means the virus is undetectable in the blood 12 weeks after completing treatment. Once cured, patients are no longer infectious and liver damage may stabilize or improve over time.
Treatment duration typically ranges from 12 to 24 weeks depending on the HCV genotype, prior treatment history, whether the patient has cirrhosis, and which combination therapy is used. Your doctor will determine the optimal treatment length for your specific situation based on these factors and your response to therapy.
Sovaldi is typically used together with ribavirin, which is known to cause serious birth defects. Therefore, pregnancy must be avoided during treatment and for at least 6 months after treatment ends. Both female patients and female partners of male patients must use effective contraception during and after treatment. Always discuss family planning with your doctor before starting therapy.
Sovaldi must not be taken with rifampicin, St. John’s wort, carbamazepine, phenobarbital, or phenytoin, as these drugs significantly reduce sofosbuvir blood levels and treatment effectiveness. Amiodarone should also be avoided due to the risk of serious, life-threatening bradycardia (dangerously slow heart rate). Always provide your doctor with a complete list of all medications, supplements, and herbal products you are taking.
References
This article is based on the following evidence-based sources. All medical claims are supported by peer-reviewed research and international clinical guidelines.
- European Medicines Agency (EMA). Sovaldi (sofosbuvir) — Summary of Product Characteristics. EMA/CHMP. Last updated 2024. Available at: ema.europa.eu
- U.S. Food and Drug Administration (FDA). Sovaldi — Prescribing Information. FDA. Revised 2023. Available at: fda.gov
- World Health Organization (WHO). Updated recommendations on treatment of adolescents and children with chronic HCV infection, and HCV simplified service delivery and diagnostics. WHO Guidelines. 2022.
- European Association for the Study of the Liver (EASL). EASL recommendations on treatment of hepatitis C: Final update of the series. Journal of Hepatology. 2020;73(5):1170-1218. doi:10.1016/j.jhep.2020.08.018
- AASLD-IDSA. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2023.
- Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. New England Journal of Medicine. 2013;368(20):1878-1887. doi:10.1056/NEJMoa1214853
- Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. New England Journal of Medicine. 2013;368(20):1867-1877. doi:10.1056/NEJMoa1214854
- WHO. Global Hepatitis Report 2024. World Health Organization. 2024.
Medical Editorial Team
This article has been written and reviewed by the iMedic medical editorial team, consisting of licensed physicians with expertise in hepatology, gastroenterology, and clinical pharmacology. Our content follows the GRADE evidence framework and adheres to international guidelines from the WHO, EMA, FDA, EASL, and AASLD.
All medical information is based on systematic reviews, meta-analyses, and randomized controlled trials (Evidence Level 1A). We follow EASL and AASLD-IDSA clinical practice guidelines for hepatitis C treatment.
Our content is independently produced without pharmaceutical company funding or sponsorship. All potential conflicts of interest are declared. Content is regularly updated to reflect the latest evidence.
Last medical review: | Next scheduled review: